Condition: Recurrent T Acute Lymphoblastic Leukemia · Refractory T Acute Lymphoblastic Leukemia · Refractory T Lymphoblastic Lymphoma · Sponsor: SWOG Cancer Research Network
This phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Chemotherapy drugs, such as OBI-3424, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. OBI-3424 may reduce the amount of leukemia in the body.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham Cancer Center | Birmingham, Alabama, United States | Active Not Recruiting |
| Kingman Regional Medical Center | Kingman, Arizona, United States | Recruiting |
| Arkansas Children's Hospital | Little Rock, Arkansas, United States | Recruiting |
| PCR Oncology | Arroyo Grande, California, United States | Recruiting |
| City of Hope Comprehensive Cancer Center | Duarte, California, United States | Recruiting |
| Loma Linda University Medical Center | Loma Linda, California, United States | Recruiting |
| Children's Hospital of Orange County | Orange, California, United States | Recruiting |
| Children's Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Alfred I duPont Hospital for Children | Wilmington, Delaware, United States | Recruiting |
| Golisano Children's Hospital of Southwest Florida | Fort Myers, Florida, United States | Recruiting |
| Memorial Regional Hospital/Joe DiMaggio Children's Hospital | Hollywood, Florida, United States | Recruiting |
| Johns Hopkins All Children's Hospital | St. Petersburg, Florida, United States | Recruiting |
+ 151 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04315324